Our Platforms

We are developing and advancing novel platform technologies to usher in a new era of immunotherapy

At BioNTech, we apply our deep expertise in immunology, drug discovery and fundamental research to develop and advance a toolbox of groundbreaking technologies spanning four drug classes to provide novel treatments and vaccines for people around the world to improve global health.

With a deep understanding of the underlying science, and based on nearly two decades of groundbreaking research, mRNA therapeutics are our most advanced assets. In addition, we use the specific properties of cell therapies, antibodies and small molecules, or even synergistic combinations of those different drug classes, to address the treatment challenges for a range of cancer and infectious disease indications.

Broadening the treatment universe

We are continuously building out our platforms and approaches aiming to harness the full power of the immune system and provide better medicines for patients worldwide.

		
				<img src="/int/en/home/pipeline-and-products/platforms/our-platforms/_jcr_content/content-area/root/container/container_1822777865/highlight_text/image.coreimg.png/1652940629977/bnt-tlf-6633.png" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
				
			We are continuously building out our platforms
		
			and approaches aiming to harness the full power
		
			of the immune system and provide
		
			better medicines for patients worldwide.

Learn more about our platforms here

mRNA-based
platforms

antibody-based
platforms

cell therapy-based platforms

small molecule-based platforms

Learn more about our drug classes

mRNA Therapeutics

We use mRNA to deliver genetic information to cells, where it translates this genetic information into proteins for therapeutic effect. We are developing a portfolio of immunotherapies that use four mRNA formats and three formulations to develop new vaccines for the treatment of cancer and or prevention of infectious diseases.

Find out more

Engineered Cell Therapies

We are developing a range of novel cell therapies in which the patient’s T cells are modified to target cancer-specific antigens. These include two platforms for the treatment of solid tumors: chimeric antigen receptor (CAR T) cells and T cell receptor (TCR) programs. We are also combining our cell therapy programs with a supercharging technology based on our mRNA FixVac platform to enhance the activity and persistence of our engineered T cell candidates in vivo.

Find out more

Antibodies

In collaboration with Genmab, we are developing next-generation bispecific antibodies to target immune checkpoints that modulate the patient’s immune response to cancer. We are also exploring additional targeted cancer antibody approaches using our in-house and recently acquired antibody capabilities.

Find out more

Small Molecule Immunomodulators

We use small molecules to augment the activity of other drug classes by inducing specific and discrete patterns of immunomodulation. We are developing a small molecule toll-like receptor 7 (TLR7) immunomodulator for the treatment of solid tumors.

Find out more

Our Platforms

We are developing and advancing novel platform technologies to usher in a new era of immunotherapy

Broadening the treatment universe